Molecular Basis of Cancer

Molecular Basis of Cancer

Molecular Basis of Cancer

On this page

Oncogenes & Growth Signals - Go-Go Growth Genes

  • Oncogenes: Mutated proto-oncogenes; drive uncontrolled cell growth (gain-of-function). "Accelerator ON".
  • Activation:
    • Point mutation: RAS (KRAS, HRAS, NRAS).
    • Amplification: HER2/neu (breast), NMYC (neuroblastoma).
    • Translocation: BCR-ABL (CML), MYC-IgH (Burkitt's).
  • Pathway Hijack:
  • Key Examples by Class:
    • Receptors: EGFR (lung adeno); HER2/neu (ERBB2) (breast, ovary, gastric ca). 📌 "HER 2 much growth".
    • Transducers: RAS (pancreas, colon, lung); BRAF (melanoma); ABL (CML).
    • Nuclear Factors: MYC (Burkitt's, neuroblastoma); drives growth, angiogenesis.

RAS mutations (KRAS, HRAS, NRAS) affect ~15-20% of human cancers; a key oncogene family.

Tumor Suppressors & Genome Guardians - Stop Signs & Fix-It Crew

  • Function: Genes that normally inhibit cell proliferation or promote DNA repair. Loss of function (LOF) → cancer.
    • Knudson's "two-hit" hypothesis: both alleles inactivated for cancer development.
  • Key Examples:
    • RB (Retinoblastoma): "Governor". Controls G1/S checkpoint by binding E2F.
      • Inactive when hyperphosphorylated by CyclinD-CDK4/6.
      • Associated: Retinoblastoma, osteosarcoma.
    • TP53 (p53): "Guardian". Responds to DNA damage.
      • Actions: Cell cycle arrest (via p21), DNA repair, Apoptosis (via BAX).
      • Li-Fraumeni syndrome (germline).
-   **APC**: Degrades β-catenin (WNT pathway). Familial Adenomatous Polyposis (FAP).
-   **BRCA1/BRCA2**: DNA repair (homologous recombination). ↑Breast, ovarian cancer risk.
-   **CDKN2A (p16<sup>INK4a</sup>)**: Inhibits CDK4/6 → keeps RB active.

⭐ TP53 is mutated in >50% of human cancers, leading to genomic instability. Rb loss in retinoblastoma and cancer progression

Epigenetics & Non-Coding RNAs - Silent Gene Tweaks

  • Epigenetics: Heritable gene expression changes without DNA sequence alteration.
    • DNA Methylation:
      • Promoter hypermethylation → silences Tumor Suppressor Genes (TSGs) (e.g., CDKN2A (p16), MLH1).
      • Global hypomethylation → activates oncogenes.
    • Histone Modification: Acetylation (↑activity), deacetylation (↓activity). Dysregulated 'histone code'.
  • Non-Coding RNAs (ncRNAs): Regulatory RNAs; not translated.
    • MicroRNAs (miRNAs): ~22 nt. Post-transcriptional gene silencing.
      • OncomiRs (promote cancer): e.g., miR-21, miR-17-92 cluster.
      • Tumor suppressor miRNAs: e.g., let-7, miR-34a.
    • Long Non-Coding RNAs (lncRNAs): >200 nt. Diverse roles. E.g., HOTAIR, MALAT1. Epigenetic gene regulation mechanisms in cancer

⭐ Promoter hypermethylation of key tumor suppressor genes (e.g., CDKN2A (p16), MLH1, BRCA1) is a common epigenetic event driving carcinogenesis.

Immortality, Angiogenesis, Metastasis - Advanced Aggression

  • Immortality (Limitless Replication):
    • Telomerase (hTERT) activation: prevents telomere shortening.
    • Evasion of apoptosis: e.g., p53 mutations, ↑BCL-2 family proteins.
    • Bypass senescence signals.
  • Angiogenesis (New Blood Vessel Formation):
    • "Angiogenic switch": balance shifts to pro-angiogenic factors (VEGF, bFGF).
    • Hypoxia (via HIF-1α) is a potent inducer.
    • Tumor vessels are often abnormal: leaky, tortuous. Tumor angiogenesis showing irregular blood vessels
  • Metastasis (Distant Spread):
    • Sequential steps: local invasion → intravasation → systemic transport → extravasation → colonization.
    • Epithelial-Mesenchymal Transition (EMT): crucial for motility; ↓E-cadherin, ↑N-cadherin, ↑vimentin.
    • Matrix Metalloproteinases (MMPs) degrade ExtraCellular Matrix (ECM).

⭐ The "cadherin switch" (loss of E-cadherin, gain of N-cadherin) is a hallmark of EMT, facilitating tumor cell invasion.

High‑Yield Points - ⚡ Biggest Takeaways

  • Proto-oncogenes (e.g., RAS, MYC) and Tumor Suppressor Genes (e.g., TP53, RB) are critical.
  • TP53 ("guardian of the genome") is the most commonly mutated gene, vital for apoptosis.
  • RB gene controls the G1/S checkpoint; its loss drives proliferation.
  • RAS mutations cause constitutive activation of growth signaling pathways.
  • BRCA1/BRCA2 defects impair DNA repair, predisposing to breast and ovarian cancers.
  • Telomerase reactivation enables cancer cell immortality_._

Practice Questions: Molecular Basis of Cancer

Test your understanding with these related questions

The following gene mutation protects tumor cells from apoptosis:

1 of 5

Flashcards: Molecular Basis of Cancer

1/10

_____ is the most commonly mutated gene in sporadic breast carcinomas

TAP TO REVEAL ANSWER

_____ is the most commonly mutated gene in sporadic breast carcinomas

TP53

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial